A Phase 1, Single Center, Randomized, Double-Blind, Placebo-Controlled Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetic Profiles of Oral CPSI-2364 in Healthy Subjects

Trial Profile

A Phase 1, Single Center, Randomized, Double-Blind, Placebo-Controlled Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetic Profiles of Oral CPSI-2364 in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 22 Aug 2012

At a glance

  • Drugs Semapimod (Primary)
  • Indications Crohn's disease; Psoriasis; Rheumatoid arthritis; Ulcerative colitis
  • Focus Adverse reactions
  • Sponsors Cytokine PharmaSciences
  • Most Recent Events

    • 14 Nov 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 18 Oct 2009 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top